Calibration of Low-Frequency, Wide-Field Radio Interferometers Using Delay/Delay-Rate Filtering

We present a filtering technique that can be applied to individual baselines of wide-bandwidth, wide-field interferometric data to geometrically select regions on the celestial sphere that contain primary calibration sources. The technique relies on the Fourier transformation of wide-band frequency spectra from a given baseline to obtain one-dimensional "delay images", and then the transformation of a time-series of delay images to obtain two-dimensional "delay/delay-rate images." Source selection is possible in these images given appropriate combinations of baseline, bandwidth, integration time and source location. Strong and persistent radio frequency interference (RFI) limits the effectiveness of this source selection owing to the removal of data by RFI excision algorithms. A one-dimensional, complex CLEAN algorithm has been developed to compensate for RFI-excision effects. This approach allows CLEANed, source-isolated data to be used to isolate bandpass and primary beam gain functions. These techniques are applied to data from the Precision Array for Probing the Epoch of Reionization (PAPER) as a demonstration of their value in calibrating a new generation of low-frequency radio interferometers with wide relative bandwidths and large fields-of-view.Comment: 17 pages, 6 figures, 2009AJ....138..219

Feature-Based Change Detection Reveals Inconsistent Individual Differences in Visual Working Memory Capacity

Visual working memory (VWM) is a key cognitive system that enables people to hold visual information in mind after a stimulus has been removed and compare past and present to detect changes that have occurred. VWM is severely capacity limited to around 3–4 items, although there are robust individual differences in this limit. Importantly, these individual differences are evident in neural measures of VWM capacity. Here, we capitalized on recent work showing that capacity is lower for more complex stimulus dimension. In particular, we asked whether individual differences in capacity remain consistent if capacity is shifted by a more demanding task, and, further, whether the correspondence between behavioral and neural measures holds across a shift in VWM capacity. Participants completed a change detection (CD) task with simple colors and complex shapes in an fMRI experiment. As expected, capacity was significantly lower for the shape dimension. Moreover, there were robust individual differences in behavioral estimates of VWM capacity across dimensions. Similarly, participants with a stronger BOLD response for color also showed a strong neural response for shape within the lateral occipital cortex, intraparietal sulcus (IPS), and superior IPS. Although there were robust individual differences in the behavioral and neural measures, we found little evidence of systematic brain-behavior correlations across feature dimensions. This suggests that behavioral and neural measures of capacity provide different views onto the processes that underlie VWM and CD. Recent theoretical approaches that attempt to bridge between behavioral and neural measures are well positioned to address these findings in future work

The Dixmier property and tracial states for C*-algebras

A.T. was partially supported by an NSERC Postdoctoral Fellowship and through the EPSRC grant EP/N00874X/1. Acknowledgements We are grateful to Luis Santiago for helpful discussions at an early stage of this investigation. We would also like to thank the referee for providing helpful comments, which have led to a number of improvements.Peer reviewedPublisher PD

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen